Dwight Moxie - 31 Jan 2024 Form 4 Insider Report for Revance Therapeutics, Inc.

Signature
/s/ Dwight Moxie
Issuer symbol
N/A
Transactions as of
31 Jan 2024
Net transactions value
$0
Form type
4
Filing time
02 Feb 2024, 16:48:12 UTC
Previous filing
07 Sep 2023
Next filing
04 Mar 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RVNC Common Stock Award $0 +90,000 +204% $0.000000 134,066 31 Jan 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RVNC Performance Stock Units Award $0 +135,000 $0.000000 135,000 31 Jan 2024 Common Stock 135,000 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to the Restricted Stock Unit shall vest in three (3) equal annual installments beginning from February 15, 2025, subject to the reporting person's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each vesting date.
F2 The performance-based RSUs (PSUs) granted to the reporting person on January 31, 2024, represent the right to receive, following vesting, a number of shares of Common Stock up to 150% of the number of PSUs. The number of shares of Common Stock acquired upon vesting of the PSUs is contingent upon the achievement of a preestablished performance metric, as approved by the Company's Compensation Committee, over a four-year performance period, subject to time based service requirements and continuous employment with the Company through the vesting dates.
F3 The number of securities reported represents the maximum shares that can be earned.